{
    "medicine_id": "e5e421b6d29c2732b48b83afe5da183ad5bf5b13",
    "platform_id": "DB00038",
    "metadata": {
        "name": "Neumega 5 mg 1mL Kit",
        "composition": "5 mg 1mL Oprelvekin",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia Label",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Oprelvekin promotes hematopoiesis by stimulating megakaryocytopoiesis and thrombopoiesis It is used in adult patients with nonmyeloid malignancies to prevent severe thrombocytopenia and reduce the need for platelet transfusions following therapies that cause myelosuppression Its use is prioritized in patients who are at an elevated risk for developing severe thrombocytopenia In clinical trials oprelvekin has shown potent thrombopoietic activity in individuals with compromised hematopoiesis",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}